Micafungin for therapy of invasive candidiasis in solid organ transplant recipients;La micafungina en el tratamiento de la candidiasis invasiva en pacientes sometidos a trasplante de órgano sólido

Revista Iberoamericana de Micologia

Volumn 26, Issue 1, 2009, Pages 65-68

  Fortún Abete, Jesús ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Invasive candidiasis; Micafungin; Transplantation

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CYCLOSPORIN; CYTOCHROME P450; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; PREDNISONE; RAPAMYCIN; RIFAMPICIN; RITONAVIR; TACROLIMUS; VORICONAZOLE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANDIDA; CANDIDEMIA; DIARRHEA; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG SAFETY; ESOPHAGUS CANDIDIASIS; FEVER; FUNGICIDAL ACTIVITY; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOTENSION; INVASIVE CANDIDIASIS; MEDICAL LITERATURE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA AND VOMITING; ORGAN TRANSPLANTATION; PHLEBITIS; REVIEW; SIDE EFFECT; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTIFUNGAL AGENTS; CANDIDIASIS; CHILD; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT, NEWBORN; LIPOPEPTIDES; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

CANDIDA;

EID: 67650711064     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-1406(09)70011-7     Document Type: Review

References (33)

1. Alvarez-Leal M., Contreras-Hernandez D., Chavez A., Diaz-Contreras J.A., Careaga-Olivares J., Zuñiga-Charles M.A., Reynoso M.C., and Hernandez-Tellez A. Leukocyte aryl-sulfatase A activity in patients with alcohol-related cirrhosis. Am J Hum Biol 13 (2001) 297-300
2. Astellas Pharma US. Mycamine (micafungin sodium) for injection: US prescribing information (online). Disponible en: http://www.astellas.us/docs/mycamine-ic.xml
3. Cornely O.A. Pooled analysis of safety for micafungin. 47th Iterscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (2007) 17-20 September; poster M-1175
4. Dufour J.F., Zimmermann A., and Reichen J. Increased hepatic lysosomal activity in biliary cirrhosis originates from hepatocytes rather than from macrophages. J Hepatol 20 (1994) 524-530
5. European Medicines Agency. Mycamine: summary of product characteristics (online). Disponible en: http://www.emea.europa.eu/humandocs/PDFs/EPAR/mycamine/H-734-PI-en-pdf
6. Forrest G.N., Rasetto F., Akpek G., and Philosophe B. Safety and efficacy of micafungin in transplantation recipients. Transplantation 82 (2006) 1549
7. Hashino S., Morita L., Takahata M., Onozawa M., Nakagawa M., Kawamura T., Fujisawa F., Kahata K., Izumiyama K., Yonezumi M., Chiba K., Kondo T., and Asaka M. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol 87 (2008) 91-97
8. Hebert M.F., Blough D.K., Townsend R.W., Allison M., Buell D., Keirns J., and Bekersky I. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45 (2005) 1018-1024
9. Hebert M.F., Smith H.E., Marbury T.C., Swan S.K., Smith W.B., Townsend R.W., Duell D., Keirns J., and Bekersky I. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 45 (2005) 1145-1152
10. Hebert M.F., Townsend R.W., Austin S., Balan G., Blough D.K., Buell D., Keirns J., and Bekersky I. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 45 (2005) 954-960
11. Heresi G.P., Gerstmann D.R., Reed M.D., Van den Anker J.N., Blumer J.L., Kovanda L., Keirns J.J., Buell D.N., and Kearns G.L. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 25 (2006) 1110-1115
12. Hirata K., Aoyama T., Matsumoto Y., Ogawa F., Yamazaki H., Kikuti A., and Yamamoto Y. Pharmacokinetics of antifungal agent micafungin in critically ill patients receiving continuous hemodialysis filtration. Yakugaku Zasshi 127 (2007) 897-901
13. Keirns J., Sawamoto T., Holum M., Buell D., Wisemandle W., and Alak A. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob Agents Chemother 51 (2007) 787-790
14. Kishino S., Ohno K., Shimamura T., and Furukawatodo H. Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients. Clin Transplant 18 (2004) 676-680
15. Kuse E.R., Chetchotisakd P., Da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., Sekhon J.S., Freire A., Ramasubramanian V., Demeyer I., Nucci M., Leelarasamee A., Jacobs F., Decruyenaere J., Pittet D., Ullmann A.J., Ostrosky-Zeichner L., Lortholary O., Koblinger S., Diekmann-Berndt H., Cornely O.A., and Micafungin Invasive Candidiasis Working Group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369 (2007) 1519-1527
16. Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 78 (2007) 275-282
17. Messer S.A., Diekema D.J., Boyken L., Tendolkar S., Hollis R.J., and Pfaller M.A. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 44 (2006) 324-326
18. Mochizuki N., Matsumoto K., Ohno K., Shimamura T., Furukawa H., Todo S., and Kishino S. Effects of hepatic CYP3A4 activity on disposition of micafungin in liver transplant recipients with markedly small-for-size grafts. Transplant Proc 38 (2006) 3649-3650
19. Narumi S., Hakamada K., Toyoki Y., et al. Influence of antifungal agents on trough level of tacrolimus. Am J Transplant 5 Supl 11 (2005) 474
20. Paderu P., Garcia-Effron G., Balashov S., Delmas G., Park S., and Perlin D.S. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 51 (2007) 2253-2256
21. Pappas P.G., Rotstein C.M., Betts R.F., Nucci M., Talwar D., De Waele J.J., Vazquez J.A., Dupont B.F., Horn D.L., Ostrosky-Zeichner L., Reboli A.C., Suh B., Digumarti R., Wu C., Kovanda L.L., Arnold L.J., and Buell D.N. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45 (2007) 883-893
22. Park S., Nelly J., and Nielsen Kahn J. Specific substitutions in the echinocandins target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida spp. isolates. Antimicrob Agents Chemother 49 (2005) 3264-3273
23. Perlin D.S. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 10 (2007) 121-130
24. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., and Diekema D.J. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46 (2008) 150-156
25. Sakaeda T., Iwaki K., Kakumoto M., Nishikawa M., Niwa T., Jin J.S., Nakamura T., Nishiguchi K., Okamura N., and Okumura K. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol 57 (2005) 759-764
26. Shimoeda S., Ohta S., Kobayashi H., Saitou H., Kubota A., Yamato S., Shimada K., Sasaki M., and Kawano K. Analysis of the blood level of micafungin involving patients with haematological diseases: new findings regarding combination therapy with tacrolimus. Biol Pharm Bull 28 (2005) 477-480
27. Takakura S., Fujihara N., Saito T., Kudo T., Iinuma Y., and Ichiyama S. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 53 (2004) 283-289
28. Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 23 (2004) 805-812
29. Ugazio G., Artizzu M., Pani P., and Dianzani M.U. The changes in some hydrolytic enzymes in carbon tetrachloride-induced fatty livers. Biochem J 90 (1964) 109-116
30. Undre N., Stevenson P., and Amakye D.D. Rifampin and ritonavir do not affect the pharmacokinetics of micafungin (FK-463), an echinocandin antifungal. Clin Microbiol Infect 10 Suppl 3 (2004) 279
31. Undre N., Stevenson P., and Brooks A. Itraconazole does not affect the pharmacokinetics of micafungin (FK-463). European Congress of Clinical Microbiology and Infectious Diseases and the 25th International Congress of Chemotherapy. Munich (2007) Abstract p970
32. Undre N., Stevenson P., and Wilbarham D. Amphotericin B does not affect the pharmacokinetics of micafungin (FK-463). European Congress of Clinical Microbiology and Infectious Diseases and the 25th International Congress of Chemotherapy. Munich (2007) Abstract p971
33. Van Burik J.A., Ratanatharathorn V., Stepan D.E., Miller C.B., Lipton J.H., Vesole D.H., Bunin N., Wall D.A., Hiemenz J.W., Satoi Y., Lee J.M., Walsh T.J., and National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39 (2004) 1407-1416